A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma

BACKGROUND: Esophageal cancer responds poorly to conventional radiotherapy, chemotherapy, and/or surgery. Immunotherapy works by boosting the body’s immune system, and preoperative immunotherapy combined with chemotherapy may increase the survival rate of patients with esophageal cancer. Here we fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaodong, Xu, Congcong, Qiu, Hongbin, Chen, Dong, Zhu, Kanghao, Zhang, Bo, Zhang, Jian, Xu, Anyi, Wang, Chunguo, Shen, Jianfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987875/
https://www.ncbi.nlm.nih.gov/pubmed/35402596
http://dx.doi.org/10.21037/atm-21-6931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987875/
https://www.ncbi.nlm.nih.gov/pubmed/35402596
http://dx.doi.org/10.21037/atm-21-6931

Ejemplares similares